General information

Announcements(2)

Program

Sessions

Search presentations

Download PDF for print

Timetable

Mon. Mar 16, 2026

Tue. Mar 17, 2026

Wed. Mar 18, 2026

web_header.png

web_icon.png

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

Enter the password to view the abstracts.<br>The password will be emailed to those who have completed the registration.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Program Type

Announcements

Profile management

Bookmark

Novel therapeutic potential of targeting HMGB1 in irritable bowel syndrome

Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders. IBS is characterized by abdominal pain and altered bowel habits, including constipation, diarrhea or both. Psychological factors, the immune system, gut microbiota, epithelial permeability, intestinal motility, visceral sensing and altered brain-gut axis interactions have been linked to IBS. No treatment option fits all patients due to the pathogenesis and pathophysiology of IBS. In this symposium, we will introduce and discuss the novel candidates for IBS treatment that target delta-opioid receptor, transient receptor potential (TRP) channel, descending pain inhibitory pathways, and high mobility group box 1 (HMGB1).

The 99th Annual Meeting of the Japanese Pharmacological Society

Presentation Information

[1-S-34]Novel therapeutic potential of targeting HMGB1 in irritable bowel syndrome

Keywords:

Password required to view

Comment